Background
==========

Elderly populations, defined as those aged 65 years and above, and, more specifically, elderly people with underlying conditions, are at increased risk for hospitalisation due to influenza \[[@r1]\]. Influenza may also increase the severity of underlying chronic lung diseases, probably through inflammatory processes \[[@r2]\]. Viral pneumonia due to influenza seems to predispose to myocardial infarction, and congestive heart failures are more common during influenza seasons \[[@r3]\]. Patients with cancer treated with chemotherapy \[[@r4]\] and diabetic patients are more vulnerable to influenza. Their impaired immune response \[[@r5]\] could also affect host response to vaccination \[[@r6],[@r7]\]. Evidence of the effectiveness of influenza vaccination in preventing severe clinical outcomes was recently described as low or very low among elderly people \[[@r8]\], and among patients with cancer \[[@r9]\], diabetes mellitus \[[@r10]\], lung diseases \[[@r11]\] \[[@r12]\], or cardiovascular diseases \[[@r13]\].

Despite the Council of the European Union and the World Health Organization's (WHO) recommendations to annually vaccinate elderly people \[[@r14],[@r15]\], influenza vaccine coverage among elderly people remains below the 75% target in most European countries \[[@r16]\].

In this context, post-marketing studies to estimate the influenza vaccine effectiveness (IVE) among elderly people are needed to inform about vaccination benefits for vaccinees, detect subgroups in which the vaccine performs less well and identify vaccine types that perform best. In 2015, to address this issue, the Integrated Monitoring of Vaccines in Europe plus (I‑MOVE+) consortium initiated a network of hospitals across Europe to measure IVE against laboratory-confirmed hospitalised influenza among elderly people.

The WHO recommended to include in the 2015/16 trivalent influenza vaccine for the northern hemisphere an A/California/7/2009 (H1N1)pdm09-like virus, an A/Switzerland/9715293/2013 (H3N2)-like virus and a B/Phuket/3073/2013-like virus (Yamagata lineage) \[[@r17]\].

In the 2015/16 influenza season in Europe, influenza A(H1N1)pdm09 and influenza B (mainly Victoria lineage) viruses predominated \[[@r18]\]. We conducted a multicentre hospital-based test-negative design (TND) case--control study to measure the 2015/16 seasonal IVE against hospitalisation with influenza A(H1N1)pdm09 and influenza B among elderly people in Europe, by risk groups and for specific vaccine types.

Methods
=======

Study sites and design
----------------------

We set up a European network of 27 hospitals in 11 countries (Croatia, Finland, France, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal, Romania and Spain) ([Figure 1](#f1){ref-type="fig"}), organised in 12 study sites (in Spain, Navarre region hospitals had their own coordination centre). Each study site adapted a generic protocol to their local setting \[[@r19],[@r20]\]. Monitoring visits were organised to ensure the study was done similarly across hospitals. We conducted a multicentre TND case--control study.

![Location of the hospitals participating in the I-MOVE + study, Europe, influenza season 2015/16 (n = 27 hospitals)](eurosurv-22-30580-f1){#f1}

Study period
------------

In each study site, the study period started at least two weeks after the beginning of the vaccination campaign in the respective countries and lasted from the week of the first detection of a laboratory-confirmed case of influenza to the week of the last laboratory-confirmed case of influenza. We defined different study periods for influenza A(H1N1)pdm09 and B.

Study population
----------------

Our study population included all community dwelling patients aged 65 years and above who had no contraindication for influenza vaccination or previous laboratory-confirmed influenza in the season and agreed to participate. In the participating services of each hospital, patients admitted for clinical conditions that could be related to influenza were screened for eligibility. Study physicians, nurses or collaborating medical staff asked patients about onset of symptoms compatible with the definition of a severe acute respiratory infection (SARI) in the previous 7 days.

We defined a SARI case as a hospitalised patient with at least one systemic (fever or feverishness, malaise, headache, myalgia or deterioration of general or functional condition) and at least one respiratory sign or symptom (cough, sore throat or shortness of breath) at admission, or within 48 hours after admission.

Data collection
---------------

The hospital study teams swabbed patients meeting the SARI case definition. Specimens were tested by RT-PCR and patients classified as influenza A(H1N1)pdm09 cases, influenza B cases, other influenza cases or controls if their specimens tested negative for any influenza virus.

The hospital study teams collected information on patients' age and sex, influenza vaccination status including date and brand of the 2015/16 vaccine and the status in two previous seasons and underlying conditions listed for clinical risk groups recommended for influenza vaccination \[[@r21]\]. The underlying conditions included diabetes mellitus, obesity (defined as body mass index ≥ 30 kg/m2), cardiovascular conditions (such as congenital heart disease, congestive heart failure and coronary artery disease), lung diseases (such as chronic obstructive pulmonary disease, cystic fibrosis, asthma), renal and rheumatologic diseases, cancer, stroke, dementia and cirrhosis. Information on number of hospitalisations for underlying conditions in the previous 12 months, number of general practitioners (GP) visits in the previous three months, smoking status and functional impairment (based on Barthel index score \[[@r22]\]) was also collected.

Information on demographics and underlying conditions were collected from interviews with patients (or their relatives) and hospital and/or primary care databases. In study sites with no vaccination register, vaccination status was collected through interview with patients. For patients vaccinated or unable to provide their vaccination status, study sites called patients' GP or pharmacists to retrieve vaccination status, date and brand ([Table 1](#t1){ref-type="table"}).

###### Vaccine types used and source of information for vaccination status by study site, I-MOVE + study, Europe, influenza season, 2015/16

  Study site        Number of hospitals   Vaccines used                                        Data sources   
  ----------------- --------------------- ---------------------------------------------------- -------------- ----------
  Croatia           1                     Inactivated subunit                                  I              I; H
  Finland           2                     Inactivated split                                    R; I; GP       I; GP; H
  France            3                     Inactivated subunit; inactivated split               I; P           I; H
  Hungary           2                     Adjuvanted                                           I; GP          I; H
  Italy             3                     Inactivated subunit; inactivated split; adjuvanted   I; GP          I; H
  Lithuania         2                     Inactivated subunit                                  I; GP          I; H
  Navarre           3                     Inactivated split                                    R              I; GP; H
  The Netherlands   1                     Inactivated subunit; inactivated split               I              I; H
  Poland            3                     Unknown                                              I; GP          I; H
  Portugal          2                     Inactivated subunit; inactivated split               R; I; GP       I; H
  Romania           3                     Inactivated subunit                                  I; GP          I; H
  Spain             2                     Inactivated subunit; inactivated split               R; I; GP       I; H

GP: general practitioner/primary care database; H: hospital database/medical charts; I: interview with patient; I-MOVE+: Integrated Monitoring of Vaccines in Europe plus; P: pharmacist; R: register.

We defined patients as vaccinated with the 2015/16 influenza vaccine if they had been vaccinated at least 14 days before symptoms onset. Otherwise, they were considered as unvaccinated.

Data analysis
-------------

We computed the IVE as (1 minus the odds ratio (OR) of vaccination between cases and controls) x 100. We performed a pooled one-stage analysis using the study site as a fixed effect and estimated IVE stratified on the presence of underlying conditions. All IVE estimates were adjusted for study site, date of SARI symptom onset and age modelled as restricted cubic splines with four knots (initial model). To adjust for additional potential confounders (sex, each group of underlying conditions, hospitalisation in the past year, more than one GP visit in the past 3 months, functional impairment, current smoking), we performed a multivariable analysis using an onward step by step modelling and analysing them as dichotomous variables. Patients with missing covariates were excluded from the analyses adjusted for these covariates. We retained in the model (full model) all covariates that changed the IVE estimate by 10% of more (relative change).

We grouped the vaccine brands in split virion, subunit or adjuvanted vaccines. To compute vaccine type-specific effectiveness, we restricted our analyses to countries with at least one patient vaccinated with a specific type.

We also computed a pooled IVE with a two-stage model, adjusting study site-specific IVE for study site-specific confounders (same as listed above) when sample size allowed. We quantified the heterogeneity between site estimates using the I-square \[[@r23]\].

To minimise the inclusion of false influenza-negatives in the control group, we carried out sensitivity analyses by restricting population to (i) patients swabbed up to three days after symptom onset and (ii) patients not treated with antivirals until the day before swabbing.

Results
=======

A total of 2,077 patients meeting the inclusion criteria were recruited in the study. We excluded 472 controls (23%) recruited outside of the study period and 65 patients (4%) with missing information on vaccination status. We included 1,274 controls and 528 cases, of which 353 (67%) were influenza A(H1N1)pdm09 positive, 105 (20%) were influenza B-positive, 41 (8%) were influenza A(H3N2)-positive, 24 (5%) were influenza A (non-subtyped)-positive, two (\<1%) were co-infected by influenza A(H1N1)pdm09 and B, one (\<1%) was co-infected by influenza A(H3N2) and B and two (\<1%) were co-infected by influenza A (non-subtyped) and B. Of the 52 cases of influenza B with a known lineage, 47 (90%) were Victoria and 5 (10%) were Yamagata. The 42 cases positive for influenza A(H3N2) did not allow us to compute IVE against this subtype.

The maximum number of influenza A(H1N1)pdm09 cases were recruited in weeks 5 to 8 of 2016 and the maximum number of influenza B and A(H3N2) cases in week 10 ([Figure 2](#f2){ref-type="fig"}).

![Cases of severe acute respiratory infection with influenza A(H3N2), A(H1N1)pdm09, and B, and negative controls, I-MOVE+ study, Europe, influenza season 2015/16 (n = 504 cases^a^; n = 1,274 controls)](eurosurv-22-30580-f2){#f2}

Overall, 216/528 cases (41%) and 694/1,274 controls (54%) had received trivalent inactivated vaccines. Among those vaccinated, 51 (6%) received adjuvanted vaccines, 338 (37%) inactivated subunit vaccines,513 (56%) inactivated split virion vaccines and the information on vaccine type was missing for 8 (1%) vaccinated patients. Age and time adjusted IVE against any influenza was 39% (95 % confidence interval (CI): 22 to 53).

Vaccine effectiveness against hospitalised influenza A(H1N1)pdm09
-----------------------------------------------------------------

We included in this analysis 355 cases of influenza A(H1N1)pdm09, of whom 138 (39%) were vaccinated, and 976 controls, of whom 543 (56%) vaccinated. The median age of A(H1N1)pdm09 cases and controls was 76 (Interquartile range (IQR) = 12 years) and 78 (IQR = 12 years) years respectively (p = 0.001). The proportion of patients with underlying conditions was similar among cases and controls except for renal (16% among cases vs 23% among controls, p = 0.003) and rheumatologic diseases (6% among cases vs 11% among controls, p = 0.033). Ten percent of A(H1N1)pdm09 cases and 3% of controls had received antivirals before swabbing (p \< 0.001) and 61% of cases vs 53% of controls were swabbed within 3 days after symptoms onset (p = 0.013) ([Table 2](#t2){ref-type="table"}).

###### Characteristics of influenza A(H1N1)pdm09 and influenza B hospitalised cases and corresponding test-negative controls included in the I-MOVE +  study, Europe, influenza season 2015/16

                                           Influenza A(H1N1)pdm09   Influenza B                                                                
  ---------------------------------------- ------------------------ ------------- -------------- --------- ------------- ------ -------------- ---------
  Median age in years (range)              76 (65--95)              --            78 (65--101)   --        76 (65--94)   --     78 (65--101)   --
  Aged 65--79 years                        235/355                  66.2          535/976        54.8^a^   76/110        69.1   566/1,015      55.8^a^
  Sex = male                               194/351                  55.3          512/975        52.5      57/110        51.8   520/1,014      51.3
  2015/16 seasonal influenza vaccination   138/355                  38.9          543/976        55.6^a^   50/110        45.5   588/1,015      57.9^a^
  2014/15 seasonal influenza vaccination   136/347                  39.2          537/958        56.1^a^   53/109        48.6   589/998        59.0^a^
  **Type of vaccine**                                                                                                                          
  Not vaccinated                           217/353                  61.5          433/970        44.6^a^   60/110        54.5   427/1012       42.2^a^
  Inactivated subunit                      77/353                   21.8          209/970        21.5      20/110        18.2   207/1012       20.5
  Inactivated split virion                 59/353                   16.7          312/970        32.2      30/110        27.3   332/1012       32.8
  Adjuvanted                               0/353                    0.0           16/970         1.6       0/110         0.0    46/1012        4.5
  **Underlying conditions**                                                                                                                    
  Diabetes                                 99/347                   28.5          277/954        29.0      31/104        29.8   284/992        28.6
  Heart disease                            215/351                  61.3          590/967        61.0      63/107        58.9   631/1,006      62.7
  Lung disease                             141/351                  40.2          438/965        45.4      46/108        42.6   484/996        48.6
  Immunodeficiency                         7/343                    2.0           34/942         3.6       10/106        9.4    32/986         3.2^a^
  Cancer                                   93/350                   26.6          263/963        27.3      19/105        18.1   280/1,001      28.0^a^
  Nutritional deficiency                   16/239                   6.7           65/723         9.0       9/84          10.7   51/753         6.8
  Renal disease                            54/349                   15.5          221/960        23.0^a^   20/106        18.9   236/996        23.7
  Dementia or stroke                       46/346                   13.3          160/956        16.7      17/104        16.3   156/991        15.7
  Rheumatologic disease                    15/246                   6.1           80/737         10.9^a^   11/87         12.6   83/757         11.0
  Obesity^b^                               43/349                   12.3          139/951        14.6      5/104         4.8    123/985        12.5^a^
  Any underlying condition                 325/350                  92.9          908/976        93.0      99/110        90.0   955/1,015      94.1
  ≥ 2 underlying conditions                244/347                  70.3          719/964        74.6      72/108        66.7   752/1,006      74.8
  Functional impairment^c^                 116/347                  33.4          347/948        36.6      20/109        18.3   359/988        36.3^a^
  Hospitalisation in past 12 months        152/345                  44.1          446/960        46.5      39/108        36.1   475/989        48.0^a^
  Current smoking                          79/340                   23.2          183/901        20.3      36/102        35.3   210/927        22.7^a^
  **Study sites**                                                                                                                              
  Croatia                                  16/355                   4.5           15/976         1.5       5/110         4.5    3/1,015        0.3
  Finland                                  18/355                   5.1           57/976         5.8       3/110         2.7    35/1,015       3.4
  France                                   11/355                   3.1           124/976        12.7      26/110        23.6   124/1,015      12.2
  Hungary                                  0/355                    0.0           0/976          0.0       1/110         0.9    5/1,015        0.5
  Italy                                    3/355                    0.8           102/976        10.5      10/110        9.1    249/1,015      24.5
  Lithuania                                17/355                   4.8           41/976         4.2       3/110         2.7    31/1,015       3.1
  Navarra                                  87/355                   24.5          240/976        24.6      27/110        24.5   230/1,015      22.7
  The Netherlands                          5/355                    1.4           12/976         1.2       3/110         2.7    6/1,015        0.6
  Poland                                   17/355                   4.8)          14/976         1.4       6/110         5.5    9/1,015        0.9
  Portugal                                 14/355                   3.9           35/976         3.6       1/110         0.9    1/1,015        0.1
  Romania                                  58/355                   16.3          101/976        10.3      2/110         1.8    70/1,015       6.9
  Spain                                    109/355                  30.7          235/976        24.1      23/110        20.9   252/1,015      24.8
  **Potential for misclassification**                                                                                                          
  Antivirals before swabbing               36/353                   10.2          32/972         3.3^a^    7/107         7.5    27/1,012       2.7^a^
  Swabbing within  3 days of onset         216/355                  60.8          518/976        53.1^a^   54/110        49.1   585/1,015      57.6

I MOVE+: Integrated Monitoring of Vaccines in Europe plus.

^a^ Indicates a significant difference (p value \< 0.05) between cases and controls.

^b^ Defined as body-mass index ≥ 30 kg/m2.

^c^ Defined as Barthel score \< 100 \[[@r22]\].

One-stage pooled IVE against A(H1N1)pdm09 adjusted for onset time and age was 42% (95% CI: 22 to 57) and 39% (95% CI: 17 to 56) when further adjusted for a range of underlying conditions and hospitalisation in the previous year ([Table 3](#t3){ref-type="table"}). IVE against A(H1N1)pdm09 was 59% (95% CI: 23 to 78), 48% (95% CI: 5 to 71), 43% (95% CI: 8 to 65) and 39% (95% CI: 7 to 60) in patients with diabetes mellitus (n = 362), cancer (n = 346), lung (n = 573) and heart disease (n = 792), respectively ([Table 3](#t3){ref-type="table"}).

###### Pooled adjusted seasonal influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09 overall among elderly people, by risk groups and vaccine type, I-MOVE +  study, Europe, influenza season, 2015/16

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyses                                                          Model used for adjustment^a^   Vaccinated\    Vaccinated\   Adjusted IVE      95% CI   
                                                                                                   /cases         /controls                    
  ----------------------------------------------------------------- ------------------------------ -------------- ------------- -------------- --------------
  **Overall**                                                                                                                                  

                                                                    Initial                        138/355        543/976       42.4           22.0 to 57.4

  Full                                                              131/336                        509/923        39.4          16.6 to 55.9   

  **By risk groups**                                                                                                                           

  At least one underlying condition                                 Initial                        130/317        499/892       35.7           11.4 to 53.3

  Initial plus severity                                             35.6                           11.2 to 53.3                                

  Diabetes mellitus                                                                                                                            

  No                                                                Initial                        98/242         370/674       33.9           4.6 to 54.2

  Yes                                                               Initial                        33/96          150/266       58.5           22.8 to 77.7

  Initial plus severity                                             58.5                           22.7 to 77.8                                

  Heart disease                                                                                                                                

  No                                                                Initial                        54/131         207/372       37.3           -1.2 to 61.1

  Yes                                                               Initial                        80/211         321/581       38.4           6.5 to 59.5

  Initial plus severity                                             39.0                           7.3 to 59.9                                 

  Lung disease                                                                                                                                 

  No                                                                Initial                        61/203         250/515       39.7           8.0 to 60.4

  Yes                                                               Initial                        72/139         276/434       42.4           7.2 to 64.3

  Initial plus severity                                             42.8                           7.8 to 64.5                                 

  Cancer                                                                                                                                       

  No                                                                Initial                        93/252         375/691       35.7           6.7 to 55.7

  Yes                                                               Initial                        41/90          150/256       47.7           4.8 to 71.3

  Initial plus severity                                             47.8                           4.8 to 71.4                                 

  **Vaccine type**                                                                                                                             

  Inactivated subunit                                               Initial                        77/224         209/538       28.1           -8.6 to 52.4

  Inactivated split virion                                          Initial                        59/178         312/588       54.7           30.7 to 70.4

  **Sensitivity analyses**                                                                                                                     

  Two-stage model                                                   two-stage^b^                   132/329        527/932       49.0           13.5 to 70.0

  Restricted to patients swabbed within 3 days                      Initial                        85/216         313/518       49.1           23.8 to 66.0

  Restricted to patients not receiving antivirals before swabbing   Initial                        126/317        531/940       42.2           20.8 to 57.8
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness.

^a^ Initial: one-stage model adjusted for study site, date of symptom onset and age (modelled as restricted cubic splines). Full: one-stage model adjusted for study site, date of symptom onset, age (modelled as restricted cubic splines), lung, heart, renal disease, diabetes mellitus, cancer, obesity (body-mass index ≥ 30 kg/m^2^) and hospitalisation for underlying conditions in past year. Severity: hospitalisations for underlying conditions in the previous year.

^b^ Poland and Hungary were excluded because there were no vaccinated controls in Poland and no cases in Hungary.

IVE against A(H1N1)pdm09 was 28% (95% CI: −9 to 52) for inactivated subunit vaccines (n = 762) and 55% (95% CI: 31 to 70) for inactivated split virion vaccines (n = 716).

Study site specific IVE ranged between −152% (95% CI: −3,081 to 80) in Italy (n = 105) and 95% (95% CI: 7 to 100) in the Netherlands (n = 17) ([Table 4](#t4){ref-type="table"}). The statistical heterogeneity between study site specific IVE estimates was moderate (I2 = 36%). The two-stage pooled analysis (n = 1,261) included Croatia, Finland, France, Italy, Lithuania, Navarre, the Netherlands, Portugal, Romania and Spain. IVE was 49% (95% CI: 14 to 70). In sensitivity analyses, IVE against influenza A(H1N1)pdm09 was 42% (95% CI: 21 to 58) when restricting to patients not having received antiviral treatment (n = 1,257) and 49% (95% CI: 24 to 66) among patients swabbed within 3 days of symptoms onset (n = 734) ([Table 3](#t3){ref-type="table"}).

###### Study site specific and two-stage^a^ pooled seasonal vaccine effectiveness against hospitalised influenza A(H1N1)pdm09 among elderly people, I- MOVE + study, Europe, influenza season 2015/16 (n = 1,261)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study site         Inclusion period     Variables used for adjustment^b^       Vaccinated\   Vaccinated\   Adjusted IVE            95% CI            I-square
                                                                                 /cases        /controls                                               
  ------------------ -------------------- -------------------------------------- ------------- ------------- -------------- -------------------------- ----------
  Croatia            2016w5--2016w13      Date                                   4/16          1/15          -122.0         −4,314.5 to 88.8           --

  Finland            2015w50--2016w7      Date                                   5/18          38/57         85.0           43.7 to 96.0               --

  France             2016w4--2016w14      Date                                   3/11          84/124        83.7           32.2 to 96.1               --

  Italy              2016w5--2016w11      Date                                   2/3           47/102        -152.2         −3,081.1 to 80.0           --

  Lithuania          2016w2--2016w10      Date                                   1/17          7/41          66.8           −210.4 to 96.4             --

  Navarra            2015w46--2016w13     Date                                   46/87         169/240       45.9           5.3 to 69.1                --

  The Netherlands    2015w50--2016w7      Date                                   1/5           10/12         94.8           6.9 to 99.7                --

  Portugal           2015w51--2016w8      Date, cancer, obesity                  3/14          14/35         11.9           −372.7 to 83.6             --

  Romania            2016w3--2016w14      Date, cancer, renal disease            4/58          6/100         -22.6          −490.3 to 74.6             --

  Spain              2016w1--2016w14      Date, age, heart disease, dependency   63/100        151/206       22.5           −39.6 to 56.9              --

  two-stage pooled                   --   --                                     --            --            49.0           13.5 to 70.0               36.2%
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness; w: week (International Organisation for Standardisation (ISO) week).

^a^ Poland and Hungary were excluded from the two-stage analyses because there were no vaccinated controls in Poland and no cases in Hungary.

^b^ Date of symptom onset and age modelled as restricted cubic spline with four knots.

Vaccine effectiveness against hospitalised influenza B
------------------------------------------------------

We included in this analysis 110 cases of influenza B, of whom 50 (46%) were vaccinated and 1,015 controls, of whom 588 (58%) vaccinated. The median age of cases and controls were 76 (IQR: 12 years) and 78 years (IQR: 12 years) respectively (p = 0.056). A lower proportion of cases than controls had cancer (18% vs 28%, p = 0.037), a functional impairment (18% vs 36%, p \< 0.001), and had been hospitalised in the previous 12 months (36% vs 48%, p = 0.02). The proportion of current smokers was higher among influenza B cases than among controls (35% vs 23%, p = 0.007) ([Table 2](#t2){ref-type="table"}).

One stage pooled IVE against influenza B adjusted for symptom onset time and age was 52% (95% CI: 24 to 70) and 47% (95% CI: 13 to 68) when further adjusted for a range of underlying conditions and hospitalisation in the previous year ([Table 5](#t5){ref-type="table"}). IVE was 62% (95% CI: 5 to 85), 60% (95% CI: 18 to 80) and 36% (95% CI: −23 to 67) in patients with diabetes mellitus (n = 302), lung (n = 520) and heart disease (n = 675), respectively.

###### Pooled adjusted seasonal vaccine effectiveness against hospitalised influenza B among elderly people overall and by risk groups, I-MOVE + study, Europe, influenza season 2015/16

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                    Model used for adjustment^a^   Vaccinated\     Vaccinated\   Adjusted IVE         95% CI      
                                                                                                   /cases          /controls                    
  ----------------------------------------------------------------- ------------------------------ --------------- ------------- -------------- --------------------
  **Overall**                                                                                                                                   

  Overall                                                           Initial                        50/110          588/1,015     51.8           23.7 to 69.5

  Overall                                                           Full                           46/101          544/948       47.0           13.1 to 67.7

  **By risk groups**                                                                                                                            

  At least one underlying condition                                 Initial                        47/97           536/929       50.2           18.7 to 69.4

  Initial plus severity                                             49.4                           17.5 to 69.0                                 

  Diabetes mellitus                                                                                                                             

  No                                                                Initial                        33/72           404/696       40.9           −7.1 to 67.4

  Yes                                                               Initial                        13/30           152/272       62.1           5.8 to 84.7

  Initial plus severity                                             62.0                           5.3 to 84.8                                  

  Heart disease                                                                                                                                 

  No                                                                Initial                        16/44           211/368       66.5           27.6 to 84.5

  Yes                                                               Initial                        32/61           354/614       36.3           −22.2 to 66.8

  Initial plus severity                                             36.1                           −22.9 to 66.7                                

  Lung disease                                                                                                                                  

  No                                                                Initial                        27/61           258/502       32.8           −28.6 to 64.8

  Yes                                                               Initial                        22/45           305/475       60.5           19.2 to 80.6

  Initial plus severity                                             59.9                           18.2 to 80.4                                 

  **Vaccine type**                                                                                                                              

  Inactivated subunit                                               Initial                        20/61           207/542       49.0           13.5 to 70.0

  Inactivated split virion                                          Initial                        30/74           332/652       54.1           18.9 to 74.0

  **Sensitivity analyses**                                                                                                                      

  two-stage model                                                   two-stage^b^                   48/86           551/858       47.0           11.9 to 68.2

  Restricted to patients swabbed within 3 days                      Initial                        31/54           358/585       25.0           −50.5 to 62.6

  Restricted to patients not receiving antivirals before swabbing   Initial                        46/99           577/985       52.3           22.8 to 70.5
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness.

^a^ Initial: one-stage model adjusted for study site, date of onset and age (modelled as restricted cubic splines). Full: one-stage model adjusted for study site, date of symptom onset, age (modelled as restricted cubic splines), lung, heart, renal disease, diabetes mellitus, cancer, obesity and hospitalisation in the previous year Severity: hospitalisations for underlying conditions in the previous year.

^b^ Croatia, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal and Romania were excluded from the two-stage analyses because there were no vaccinated controls and/or cases, respectively.

IVE against influenza B was 49% (95% CI: 14 to 70) for inactivated subunit vaccines (n = 603) and 54% (95% CI: 19 to 74) for inactivated split virion vaccines (n = 726).

Study site specific IVE ranged between 18% (95% CI: −106 to 67) in Finland (n = 38) and 76% (95% CI: −24 to 95) in Italy (n = 259) ([Table 6](#t6){ref-type="table"}). There was no statistical heterogeneity between study site specific IVE estimates (I2 = 0%). The two-stage pooled analysis (n = 944) included Finland, France, Italy, Navarre and Spain. IVE was 47% (95% CI: 12 to 68). In sensitivity analyses, IVE against influenza B was 52% (95% CI: 23 to 71) when restricting to patients not having received antiviral treatment (n = 1,084) and 25% (95%CI: −51 to 63) among patients swabbed within 3 days of symptoms onset (n = 639).

###### Study site-specific and two-stage^a^ pooled seasonal vaccine effectiveness against hospitalised influenza B among elderly people, I- MOVE + study, Europe, influenza season 2015/16

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study site                         Inclusion period         Variables used for adjustment^b^   Vaccinated\   Vaccinated\   Adjusted IVE           95% CI           I-square
                                                                                                 /cases        /controls                                             
  ---------------------------- ------------------------------ ---------------------------------- ------------- ------------- -------------- ------------------------ ----------
  Finland                      2016w8--2016w15                Date                               2/3           22/35         23.3           -1,785.9 to 96.9         --

  France                       2016w4--2016w14                Date, age, functional impairment   17/26         87/120        18.1           -105.6 to 67.4           --

  Italy                        2016w1--2016w12                Date                               2/10          121/249       75.5           -23.7 to 95.1            --

  Navarre                      2015w53--2016w17               Date                               17/27         165/230       59.4           -2.5 to 83.9             --

  Spain                        2016w2--2016w16                Date, lung disease, dependency     11/20         159/220       44.3           -48.9 to 79.1            --

  two-stage pooled (n = 944)   --                             --                                 --            --            47.0           11.9 to 68.2             0.0%
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; I MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness; w: week (International Organisation for Standardisation (ISO) week).

^a^ Croatia, Hungary, Italy, Lithuania, the Netherlands, Poland, Portugal and Romania were excluded from the two-stage analyses because there were no vaccinated controls and/or cases.

^b^ Date of onset and age modelled as restricted cubic spline with four knots.

Discussion
==========

Our results suggest that the seasonal IVE against hospitalised influenza among elderly people was moderate during the 2015/16 influenza season in Europe for influenza: 39% overall, 42% against influenza A(H1N1)pdm09 and 52% against influenza B . These estimates did not vary between categories of underlying conditions.

Data from European virological surveillance reported that most of the characterised influenza A(H1N1)pdm09 viruses belonged to the emerging subclade 6B.1, defined by haemagglutinin amino acid substitutions S162N and I216T \[[@r18]\]. Despite these genetic evolutions, A(H1N1)pdm09 viruses were considered antigenically similar to the northern hemisphere vaccine component A/California/7/2009. IVE estimates against hospitalised A(H1N1)pdm09 was consistent with the results we reported in 2012/13 and 2013/14 among hospitalised elderly people \[[@r24],[@r25]\].

In 2015/16, the circulating influenza B Victoria lineage was distinct from the Yamagata vaccine component \[[@r26]\] and there was no quadrivalent vaccine used in our study population. IVE against influenza B was close to what we reported, using the same generic protocol, in 2012/13 (66% in the 65--79 year-olds and 44% in the 80 year-olds and older) in a season with co-circulation of B Victoria and Yamagata lineages and a Yamagata vaccine component \[[@r24],[@r27]\]. These results suggest some cross-lineage protection and they are in line with previously reported data in GP-based studies \[[@r28],[@r29]\] and a meta-analysis of eight randomised controlled trials with mismatched B viruses resulting in a VE of 52% (95% CI: 19 to 72) among healthy adults \[[@r30]\]. Further studies are needed to increase the understanding of mechanisms of cross-lineage protection for influenza B and better guide policy makers in terms of recommendations for using trivalent or tetravalent seasonal vaccines.

We observed higher point estimates of IVE for the inactivated split virion vaccines compared with inactivated subunit vaccines, although the 95% CIs of the point estimates were widely overlapping. The completeness of data on vaccine type was high (1% of missing vaccine type among those vaccinated), thus these results, concurring with published data \[[@r31]-[@r33]\], could be due to differences in T-cell responses conferred by the two vaccine types \[[@r34]\]. However, they should be interpreted with caution as they may be due to random variation. Further evidence, and pooling of several years of data would be required to obtain precise vaccine type specific effectiveness. Higher adjuvant vaccine coverage would be needed to compute adjuvant vaccine specific IVE. This would be useful information to adapt influenza vaccination strategies among elderly people.

Recent reviews underlined the need for further evidence of seasonal IVE against laboratory-confirmed influenza in elderly people and patients with underlying conditions \[[@r8]-[@r13]\]. We were able to collect high quality data from 1,802 elderly patients hospitalised with SARI, making our study one of the largest hospital-based studies on IVE. The large number of participants, and a vaccine coverage close to 50%, enabled us to compute IVE against type/subtype-specific influenza among patients with specific underlying conditions. Our results suggest that, in 2015/16, the seasonal influenza vaccine provided protection against hospitalised influenza A(H1N1)pdm09 and B in the elderly with diabetes mellitus, heart and lung disease. We were unable to refine the underlying conditions categories further. To better guide vaccine recommendations, IVE among patients receiving specific treatment (e.g. statins \[[@r35],[@r36]\], chemotherapy \[[@r9],[@r37]\]) or with more specific conditions (e.g. asthma, chronic obstructive pulmonary disease) would be needed. A larger sample size would be required for such studies.

We collected information related to access to care, health conditions and smoking status. Recruited cases and controls were similar. We adjusted our estimates for study site, onset week and age. Further adjustment for potential confounders (underlying lung, heart, renal disease, diabetes mellitus, cancer, obesity and hospitalisations in the past year) did not change the estimates. However, as in any observational study, we cannot exclude unmeasured confounding leading to over- or under-estimation of the IVE.

The contribution to the pooled dataset was different between study sites. The two Spanish sites recruited 44% of the patients. The viruses circulating and vaccines used in Spain were similar to the other countries. Consequently we do not expect the over-representation of Spanish sites to have biased our overall estimates. Variations in the number of recruited individuals may be explained by differences in local influenza activity or number and size of participating hospitals/services. We believe that access to hospitalisation in case of severe influenza is similar across participating European countries. A common generic protocol and the monitoring of its implementation through on-site visits contributed to ensuring comparability of patients recruited and data collected across study sites. We measured low statistical heterogeneity based on I-square values. However, small number of estimates and large study-specific CIs may hinder adequate quantitative assessment of heterogeneity between studies \[[@r38]\]. True differences between study site specific IVE could be related to different vaccines used during this season or different immunological profiles of recruited patients including their past vaccination histories \[[@r39]\]. Larger study site-specific sample sizes are required to ensure that the differences in IVE across study sites are not due to chance. Currently, multicentre studies are necessary to obtain precise IVE estimates.

A recent publication by Foppa et al. suggested that measuring IVE against laboratory-confirmed influenza SARI hospitalisation using the TND was subject to biases if the test-negative controls were hospitalised because of an exacerbation of underlying lung disease unrelated to a respiratory infection \[[@r40]\]. In our study, cases and controls had similar prevalence of underlying lung disease. Underlying lung disease did not appear to confound IVE estimates, even when combined with a proxy of its severity (hospitalisation because of underlying conditions in the past 12 months). Cohort and TND-based IVE estimates against laboratory-confirmed hospitalised influenza in Navarre repeatedly showed similar estimates, reassuring on the appropriateness of TND at hospital level \[[@r41]\].

Several studies suggest that past influenza vaccinations may decrease or enhance current vaccine effectiveness depending on previous and current vaccine and circulating strains as well as past exposure to the virus \[[@r24],[@r32],[@r42]-[@r44]\]. A large proportion of our vaccinated population had been vaccinated in the previous season(s) but the very small number of patients with varying repeated vaccination status over the years did not allow us to measure the effect of previous vaccinations. To understand the effect of repeated vaccinations on IVE, large cohorts of individuals with different vaccination patterns and symptomatic (and asymptomatic) influenza infection status over the years would be needed.

Conclusion
==========

Our multicentre test-negative case--control study estimated that in 2015/16 the seasonal influenza vaccination prevented approximately half of the cases of hospitalisation with laboratory-confirmed influenza among vaccinated elderly people. Our results suggest that vaccination provided similar protection to elderly patients with underlying diabetes mellitus, cancer, lung and heart diseases. Because vaccination remains the most effective preventive measure against severe influenza among elderly people, increasing the vaccine coverage in this group should be a priority. This pilot season of the hospital-based I-MOVE + project proved that obtaining precise estimates of IVE against a severe influenza outcome among elderly people was feasible. Enlarging our network and its sample size will enable us to better guide vaccination strategies against severe influenza cases by comparing the performance of different vaccine types and identifying risk groups for poor response to vaccination.
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